[go: up one dir, main page]

MX363111B - Agente terapeutico para trastornos de queratoconjuntivitis. - Google Patents

Agente terapeutico para trastornos de queratoconjuntivitis.

Info

Publication number
MX363111B
MX363111B MX2015005842A MX2015005842A MX363111B MX 363111 B MX363111 B MX 363111B MX 2015005842 A MX2015005842 A MX 2015005842A MX 2015005842 A MX2015005842 A MX 2015005842A MX 363111 B MX363111 B MX 363111B
Authority
MX
Mexico
Prior art keywords
therapeutic agent
corneal
disorders
keratoconjunctive
keratitis
Prior art date
Application number
MX2015005842A
Other languages
English (en)
Other versions
MX2015005842A (es
Inventor
Kimura Kazuhiro
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50684334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX363111(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of MX2015005842A publication Critical patent/MX2015005842A/es
Publication of MX363111B publication Critical patent/MX363111B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)

Abstract

La invención actual aborda el problema de proporcionar un agente terapéutico novedoso para trastornos de queratoconjuntivitis. Como un medio para solucionar el problema, se proporciona un agente terapéutico para trastornos de queratoconjuntivitis que contiene un agonista RAR? como un ingrediente activo. El agente terapéutico exhibe un efecto de aminoración excelente en un modelo de trastorno de queratoconjuntivitis, y por lo tanto es útil como un agente terapéutico para trastornos de queratoconjuntivitis tales como úlcera de córnea, abrasión epitelial de córnea, queratitis, ojo seco, conjuntivitis, queratitis superficial crónica, erosión de córnea, trastornos persistentes de córnea, queratopatía punteada superficial, defectos epiteliales de la córnea, defectos epiteliales conjuntivales, queratoconjuntivitis seca, queratoconjuntivitis límbica superior, queratoconjuntivitis filamentosa, queratitis infecciosa, queratitis no infecciosa, conjuntivitis infecciosa y conjuntivitis no infecciosa. El agente terapéutico también es útil como un agente terapéutico para cicatrizado de córnea y cicatrizado conjuntival, ambos asociados con trastornos de queratoconjuntivitis.
MX2015005842A 2012-11-08 2013-11-07 Agente terapeutico para trastornos de queratoconjuntivitis. MX363111B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012246373 2012-11-08
PCT/JP2013/006563 WO2014073209A1 (ja) 2012-11-08 2013-11-07 角結膜障害の治療剤

Publications (2)

Publication Number Publication Date
MX2015005842A MX2015005842A (es) 2016-01-20
MX363111B true MX363111B (es) 2019-03-08

Family

ID=50684334

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005842A MX363111B (es) 2012-11-08 2013-11-07 Agente terapeutico para trastornos de queratoconjuntivitis.
MX2019002526A MX375992B (es) 2012-11-08 2013-11-07 Agente terapeutico para trastornos de queratoconjuntivitis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019002526A MX375992B (es) 2012-11-08 2013-11-07 Agente terapeutico para trastornos de queratoconjuntivitis.

Country Status (17)

Country Link
US (6) US9492431B2 (es)
EP (1) EP2918290B1 (es)
JP (3) JP6254529B2 (es)
KR (1) KR102173932B1 (es)
CN (2) CN105188753B (es)
AU (2) AU2013342882B2 (es)
BR (1) BR112015010428B1 (es)
CA (1) CA2890424C (es)
CL (2) CL2015001225A1 (es)
ES (1) ES2834111T3 (es)
HK (1) HK1219224A1 (es)
MX (2) MX363111B (es)
NZ (1) NZ708756A (es)
RU (1) RU2659203C2 (es)
SG (2) SG10201704687YA (es)
WO (1) WO2014073209A1 (es)
ZA (1) ZA201504065B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704687YA (en) 2012-11-08 2017-07-28 Univ Yamaguchi Therapeutic agent for keratoconjunctive disorders
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
JP6407145B2 (ja) 2013-05-22 2018-10-17 国立大学法人山口大学 網脈絡膜障害の抑制剤
IL295440B1 (en) 2016-06-08 2025-01-01 Clementia Pharmaceuticals Inc Methods for treating heterotopic genesis
EA039050B1 (ru) 2016-11-16 2021-11-26 Клементиа Фармасьютикалс Инк. Способы лечения множественного остеохондроматоза (мо)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678086B1 (en) 1993-01-11 1999-12-08 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
WO2001068135A2 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
PT1324970E (pt) 2000-10-02 2009-01-02 Hoffmann La Roche Novos retinóides para o tratamento de enfisema
WO2003024921A1 (en) 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
ES2325063T3 (es) 2001-09-18 2009-08-25 F. Hoffmann-La Roche Ag Agonistas de retinoide ii de urea sustituida.
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
CA2601312A1 (en) 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
CN101316584A (zh) 2005-09-27 2008-12-03 北海道公立大学法人札幌医科大学 用于预防及治疗由血管通透性亢进引起的眼病的医药
MX2008012358A (es) 2006-03-31 2008-10-09 Hoffmann La Roche Proceso para preparar compuestos retinoides.
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
US8614103B2 (en) * 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP2009235031A (ja) 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
EA026251B1 (ru) 2010-09-01 2017-03-31 Томас Джефферсон Юниверсити Способ восстановления и регенерации мышц
EP2621588A4 (en) 2010-09-27 2014-09-03 Microdose Therapeutx Inc METHODS AND COMPOSITIONS FOR TREATING DISEASE USING INHALATION
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
SG10201704687YA (en) 2012-11-08 2017-07-28 Univ Yamaguchi Therapeutic agent for keratoconjunctive disorders
JP6407145B2 (ja) 2013-05-22 2018-10-17 国立大学法人山口大学 網脈絡膜障害の抑制剤

Also Published As

Publication number Publication date
AU2018217197A1 (en) 2018-08-30
SG11201503612QA (en) 2015-06-29
US20230255937A1 (en) 2023-08-17
CN105188753A (zh) 2015-12-23
ZA201504065B (en) 2016-11-30
EP2918290A4 (en) 2016-05-18
RU2659203C2 (ru) 2018-06-28
MX2015005842A (es) 2016-01-20
US20180000782A1 (en) 2018-01-04
NZ708756A (en) 2019-07-26
WO2014073209A1 (ja) 2014-05-15
CN109589324B (zh) 2022-06-14
MX375992B (es) 2025-03-07
SG10201704687YA (en) 2017-07-28
US20150290172A1 (en) 2015-10-15
CA2890424C (en) 2020-11-17
CN109589324A (zh) 2019-04-09
US20170065562A1 (en) 2017-03-09
MX2019002526A (es) 2019-07-15
JP2018030887A (ja) 2018-03-01
US9492431B2 (en) 2016-11-15
BR112015010428B1 (pt) 2020-04-22
JP6254529B2 (ja) 2017-12-27
ES2834111T3 (es) 2021-06-16
JP6744389B2 (ja) 2020-08-19
CA2890424A1 (en) 2014-05-15
US10537556B2 (en) 2020-01-21
HK1219224A1 (zh) 2017-03-31
RU2015121628A (ru) 2016-12-27
US20190134002A1 (en) 2019-05-09
CL2015001225A1 (es) 2016-03-04
BR112015010428A2 (pt) 2017-07-11
JP6462836B2 (ja) 2019-01-30
EP2918290A1 (en) 2015-09-16
US20200345695A1 (en) 2020-11-05
AU2013342882A1 (en) 2015-06-11
KR102173932B1 (ko) 2020-11-04
KR20150082326A (ko) 2015-07-15
JPWO2014073209A1 (ja) 2016-09-08
AU2013342882B2 (en) 2018-05-17
US11471440B2 (en) 2022-10-18
CL2018001915A1 (es) 2018-08-31
CN105188753B (zh) 2018-12-18
EP2918290B1 (en) 2020-09-02
US10016395B2 (en) 2018-07-10
US9750721B2 (en) 2017-09-05
JP2019069992A (ja) 2019-05-09
AU2018217197B2 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2015005842A (es) Agente terapeutico para trastornos de queratoconjuntivitis.
MY191381A (en) Novel amino pyrimidine derivatives
MX370032B (es) Agonistas del receptor de esfingosina-1-fosfato, metodos para prepararlos y composiciones farmaceuticas que contienen los mismos como un agente activo.
CO6751270A2 (es) Compuestos y composiciones como inhibidores de la trk
MX376164B (es) Composiciones y metodos para tratar el insomnio.
MY166228A (en) Compositions comprising mixtures of semifluorinated alkanes
MX365242B (es) El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
GEP20207098B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2014004126A (es) Tratamiento de enfermedades malignas y no malignas con antagonistas de ras.
IN2014MN02380A (es)
TN2013000373A1 (en) Pharmaceutical formulation comprising inositol
WO2017218942A8 (en) COMPOSITIONS AND METHODS FOR TREATING DRY SYNDROME AND OTHER NON-KERATINIZED EPITHELIAL SURFACES WITH TRAUMA OCCURRENCE
MY166314A (en) Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
RU2019104946A (ru) Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра
MX2012002091A (es) Uso de antibioticos en aerosol para el tratamiento de la enfermedad pulmonar obstructiva cronica.
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
PH12016500980A1 (en) Amide derivatives for gpr119 agonist
AU2014365665A1 (en) Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
RU2012138767A (ru) Дисперсный композиционный материал
AU2013208087A8 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof
WO2011105902A3 (en) Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A3 (en) Antagonists of complement component 9 (c9) and uses thereof
RU2011145598A (ru) Цементная композиция для наливных полов с антистатическим эффектом